AbbVie (NYSE:ABBV) Announces Earnings Results, Misses Expectations By $0.82 EPS

AbbVie (NYSE:ABBV) released its quarterly earnings results on Friday. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82), RTT News reports. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. During the same period in the previous year, the business earned $2.79 earnings per share. AbbVie updated its FY 2025 guidance to 12.120-12.320 EPS.

AbbVie Stock Up 5.1 %

Shares of ABBV stock traded up $8.97 during mid-day trading on Friday, hitting $184.62. The company’s stock had a trading volume of 6,478,440 shares, compared to its average volume of 5,935,105. AbbVie has a 52-week low of $153.58 and a 52-week high of $207.32. The business has a 50-day moving average price of $176.43 and a 200 day moving average price of $184.84. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The stock has a market cap of $326.26 billion, a price-to-earnings ratio of 64.10, a PEG ratio of 1.77 and a beta of 0.58.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ABBV shares. BMO Capital Markets cut their price target on AbbVie from $228.00 to $208.00 and set an “outperform” rating for the company in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut their price target on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. UBS Group increased their price target on AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price target for the company in a research note on Friday, November 22nd. Finally, Citigroup cut their target price on AbbVie from $215.00 to $205.00 and set a “buy” rating for the company in a research note on Tuesday. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $205.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.